Earnest Partners LLC Lowers Position in Charles River Laboratories Intl. Inc (CRL)

Share on StockTwits

Earnest Partners LLC reduced its position in shares of Charles River Laboratories Intl. Inc (NYSE:CRL) by 1.5% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 246,937 shares of the medical research company’s stock after selling 3,752 shares during the period. Earnest Partners LLC’s holdings in Charles River Laboratories Intl. were worth $27,721,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the business. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Charles River Laboratories Intl. by 18.9% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,054 shares of the medical research company’s stock worth $326,000 after purchasing an additional 486 shares during the last quarter. Mason Street Advisors LLC boosted its stake in shares of Charles River Laboratories Intl. by 2.1% during the 1st quarter. Mason Street Advisors LLC now owns 23,822 shares of the medical research company’s stock worth $2,543,000 after purchasing an additional 488 shares during the last quarter. Oregon Public Employees Retirement Fund boosted its stake in shares of Charles River Laboratories Intl. by 3.0% during the 2nd quarter. Oregon Public Employees Retirement Fund now owns 18,409 shares of the medical research company’s stock worth $2,067,000 after purchasing an additional 536 shares during the last quarter. Atria Investments LLC boosted its stake in shares of Charles River Laboratories Intl. by 18.8% during the 1st quarter. Atria Investments LLC now owns 3,722 shares of the medical research company’s stock worth $397,000 after purchasing an additional 589 shares during the last quarter. Finally, Amalgamated Bank boosted its stake in shares of Charles River Laboratories Intl. by 6.5% during the 1st quarter. Amalgamated Bank now owns 10,547 shares of the medical research company’s stock worth $1,126,000 after purchasing an additional 642 shares during the last quarter. 97.76% of the stock is currently owned by institutional investors.

In other news, CEO James C. Foster sold 5,005 shares of the stock in a transaction dated Monday, July 2nd. The shares were sold at an average price of $110.80, for a total transaction of $554,554.00. Following the transaction, the chief executive officer now directly owns 296,676 shares in the company, valued at approximately $32,871,700.80. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director George Massaro sold 300 shares of the firm’s stock in a transaction that occurred on Monday, June 25th. The shares were sold at an average price of $115.55, for a total transaction of $34,665.00. Following the completion of the transaction, the director now owns 14,037 shares in the company, valued at approximately $1,621,975.35. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 37,324 shares of company stock worth $4,504,045. Insiders own 2.10% of the company’s stock.

Shares of CRL stock opened at $124.28 on Thursday. The stock has a market cap of $5.93 billion, a PE ratio of 21.67, a P/E/G ratio of 1.55 and a beta of 0.65. Charles River Laboratories Intl. Inc has a 1-year low of $96.70 and a 1-year high of $130.66. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.48 and a current ratio of 1.72.

Charles River Laboratories Intl. (NYSE:CRL) last announced its quarterly earnings data on Wednesday, August 8th. The medical research company reported $1.62 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.46 by $0.16. The business had revenue of $585.30 million for the quarter, compared to analyst estimates of $570.65 million. Charles River Laboratories Intl. had a net margin of 6.38% and a return on equity of 25.26%. The company’s revenue was up 24.8% on a year-over-year basis. During the same period in the prior year, the firm posted $1.29 EPS. analysts forecast that Charles River Laboratories Intl. Inc will post 5.91 earnings per share for the current fiscal year.

CRL has been the topic of several analyst reports. KeyCorp raised shares of Charles River Laboratories Intl. from a “sector weight” rating to an “overweight” rating and raised their price target for the stock from $115.85 to $130.00 in a research note on Friday, June 15th. Jefferies Financial Group reaffirmed a “buy” rating and set a $140.00 price target on shares of Charles River Laboratories Intl. in a research note on Friday, July 20th. ValuEngine raised shares of Charles River Laboratories Intl. from a “hold” rating to a “buy” rating in a research note on Wednesday, July 18th. Royal Bank of Canada raised shares of Charles River Laboratories Intl. from a “sector perform” rating to an “outperform” rating and set a $131.00 price target on the stock in a research note on Tuesday, July 17th. Finally, Argus increased their price objective on shares of Charles River Laboratories Intl. from $125.00 to $140.00 and gave the stock a “buy” rating in a report on Monday, August 27th. Seven equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Charles River Laboratories Intl. currently has an average rating of “Buy” and an average target price of $125.40.

Charles River Laboratories Intl. Profile

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

See Also: Should I follow buy, hold and sell recommendations?

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories Intl. Inc (NYSE:CRL).

Institutional Ownership by Quarter for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply